Summary
Since quipazine is a potent 5-HT agonist in peripheral organs, its possible stimulatory effects on serotoninergic receptors in the rat brain were investigated. Quipazine administration (10 mg/kg, i.p.) induced a significant decrease in the synthesis and turnover rates of serotonin in the brain stem as well as in the forebrain. It is not likely that these changes were mediated by a negative feed-back mechanism triggered by adirect action of quipazine on central 5-HT postsynaptic receptors. Indeed, in contrast to LSD and 5-methoxy-N,N-dimethyltryptamine, this compound failed to activate the 5-HT sensitive adenylate cyclase in colliculi homogenates of newborn rats. However, quipazine exerted direct effects on serotoninergic terminals. It inhibited competitively the reuptake process in synaptosomes (Ki =1.38×10−7 M) and stimulated the K+ evoked release of newly synthesized3H-5-HT in slices of the brain stem. Injected in vivo in a dose which affected 5-HT uptake and release, quipazine did not modify MAO activity. However, this activity was noncompetitively inhibited by high concentration of the drug in vitro (Ki=3.0×10−5 M). These actions are very likelyindirectly responsible for the stimulation of central 5-HT receptors.
Similar content being viewed by others
References
Aghajanian, G. K.: LSD and CNS transmission. Ann. Rev. Pharmacol.12, 157–168 (1972)
Andén, N.-E., Corrodi, H., Fuxe, K., Hökfelt, T.: Evidence for a central 5-hydroxytryptamine receptor stimulation by lysergic acid diethylamide. Brit. J. Pharmacol.34, 1–7 (1968)
Bockaert, J., Premont, J., Glowinski, J., Thierry, A. M., Tassin, J. P.: Topographical distribution of dopaminergic innervation and of dopaminergic receptors in the rat striatum. II. Distribution and characteristics of dopamine adenylate cyclase. Interaction of d-LSD with dopaminergic receptors. Brain Res. (in press, 1976)
Bourgoin, S., Faivre-Bauman, A., Benda, P., Glowinski, J., Hamon, M.: Plasma tryptophan and 5-HT metabolism in the CNS of the new born rat. J. Neurochem.23, 319–327 (1974)
Bourgoin, S., Ternaux, J. P., Boireau, A., Héry, F., Hamon, M.: Effects of halothane and nitrous oxide anaesthesia on 5-HT turnover in the rat brain. Naunyn-Schmiedeberg's Arch. Pharmacol.288, 109–121 (1975)
Briggs, I.: Actions and interactions of iontophoretically applied quipazine and monoamines on brain stem neurons. Exp. Brain. Res., Suppl.23, Abstr. 52 (1975)
Burkard, W. P.: Comparison of an in vivo and an in vitro test for evaluation of the inhibitory action of drugs on the 5-hydroxytryptamine uptake in rat brain neurons. Experientia (Basel)31, 727 (1975)
Carlsson, A., Corrodi, H., Fuxe, K., Hökfelt, T.: Effect of antidepressant drugs on the depletion of intraneuronal brain 5-hydroxytryptamine stores caused by 4-methyl-α-ethyl-metatyramine. Europ. J. Pharmacol.5, 357–366 (1969)
Carlsson, A., Davis, J. N., Kehr, W., Lindqvist, M., Atack, C. V.: Simultaneous measurement of tyrosine and tryptophan hydroxylase activities in brain in vivo, using an inhibitor of the aromatic amino acid decarboxylase. Naunyn-Schmiedeberg's Arch. Pharmacol.275, 153–168 (1972)
Costall, B., Naylor, R. J.: The role of the raphe and extrapyramidal nuclei in the stereotyped and circling responses to quipazine. J. Pharm. Pharmacol.27, 368–371 (1975)
Grabowska, M., Antkiewicz, L., Michaluk, J.: The influence of quipazine on the turnover rate of serotonin. Biochim. Pharmacol.,23, 3211–3212 (1974)
Gray, E. G., Whittaker, V. P.: The isolation of nerve endings from brain: an electron microscopic study of cell fragments derived by homogenization and centrifugation. J. Anat. (Lond.)96, 79–88 (1962)
Green, A. R., Youdim, M. B. H., Grahame-Smith, D. G.: Quipazine: its effects on rat brain 5-hydroxytryptamine metabolism, monoamine oxidase activity and behaviour. Neuropharmacology15, 173–179 (1976)
Hamon, M., Bourgoin, S., Glowinski, J.: Feedback regulation of 5-HT synthesis in rat striatal slices. J. Neurochem.20, 1727–1745 (1973)
Hamon, M., Bourgoin, S., Jagger, J., Glowinski, J.: Effects of LSD on synthesis and release of 5-HT in rat brain slices. Brain Res.69, 265–280 (1974)
Heikkila, R. E., Orlansky, H., Cohen, G.: Studies on the distinction between uptake inhibition and release of (3H)dopamine in rat brain tissue slices. Biochem. Pharmacol.24, 847–852 (1975)
Hery, F., Rouer, E., Glowinski, J.: Daily variations of serotonin metabolism in the rat brain. Brain Res.43, 445–465 (1972)
Hong, E., Pardo, E. G.: On the pharmacology of 2-(1-piperazinyl) quinoline. J. Pharmacol. exp. Ther.153, 259–265 (1966)
Hong, E., Sancilio, L. F., Vargas, R., Pardo, E. G.: Similarities between the pharmacological actions of quipazine and serotonin. Europ. J. Pharmacol.6, 274–280 (1969)
Jacoby, J. H., Howd, R. A., Levin, M. S., Wurtman, R. J.: Mechanisms by which quipazine alters brain 5-hydroxyindole metabolism. 5th Annual Meeting of the Society for Neuroscience. New York. Abstr. 390, 1975
Kebabian, J. W., Petzold, G. L., Greengard, P.: Dopamine-sensitive adenylate cyclase in caudate nucleus of rat brain, and its similarity to the “dopamine receptor”. Proc. nat. Acad. Sci. (Wash.)69, 2145–2149 (1972)
Lowry, O. H., Rosebrough, N. J., Farr, A. L., Randall, R. J.: Protein measurement with the folin phenol reagent. J. biol. Chem.193, 265–275 (1951)
Malick, J. B., Doren, E., Barnett, A.: Quipazine-induced headtwitch produced by serotonin receptor activation in mice. Fed. Proc.34, 3289 (1975)
Medon, P. J., Leeling, J. L., Phillips, B. M.: Influence of quipazine, a potential antiparkinsonian agent, on the uptake of3H-dopamine and3H-serotonin into rat striatal tissue in vitro. Life Sci.13, 685–691 (1973)
Monachon, M.-A., Burkard, W. P., Jalfre, M., Haefely, W.: Blockade of central 5-hydroxytryptamine receptors by methiothepin. Naunyn-Schmiedeberg's Arch. Pharmacol.274, 192–197 (1972)
Robinson, D. S., Lovenberg, W., Keiser, H., Sjoerdsma, A.: Effects of drugs on human blood platelet and plasma amine oxidase activity in vitro and in vivo. Biochem. Pharmacol.17, 109–119 (1968)
Rodríguez, R., Antagonism of tremorine-induced tremor by serotoninergic agents in mice. Interactions with levodopa. Life Sci.11, 535–544 (1972)
Rodríguez, R., Rojas-Ramírez, J. A., Drucker-Colín, R. R.: Serotonin-like actions of quipazine on the central nervous system. Europ. J. Pharmacol.24, 164–171 (1973)
Salomon, Y., Londos, C., Rodbell, M.: A highly sensitive adenylate cyclase assay. Analyt. Biochem.58, 541–548 (1974)
Schubert, J., Nyback, H., Sedvall, G.: Effect of antidepressant drugs on accumulation and disappearance of monoamines formed in vivo from labelled precursors in mouse brain. J. Pharm. Pharmacol.22, 136–139 (1970)
Sheard, M. H., Zolovick, A., Aghajanian, G. K.: Raphe neurons: effect of tricyclic antidepressant drugs. Brain Res.43, 690–694 (1972)
Snedecor, G. W., Cochran, W. G.: Statistical methods. Ames: Iowa State College Press 1967
Von Hungen, K., Roberts, S., Hill, D. F.: Serotonin-sensitive adenylate cyclase activity in immature rat brain. Brain Res.84, 257–267 (1975)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hamon, M., Bourgoin, S., Enjalbert, A. et al. The effects of quipazine on 5-HT metabolism in the rat brain. Naunyn-Schmiedeberg's Arch. Pharmacol. 294, 99–108 (1976). https://doi.org/10.1007/BF00692790
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00692790